MADISON, WI. SEPT. 20, 2019 – Catalent Biologics’ cell line development and biomanufacturing site in Madison is expanding with a $75 million investment expected to create at least 145 new jobs by the end of 2021, Governor Tony Evers, local leaders and company officials announced today.
“We are grateful Catalent has decided to continue investing in Wisconsin and create opportunities in Madison,” said Governor Evers. “The numerous high-paying jobs created by this expansion will require an educated workforce to support new roles, which provides another example of how backing education in Wisconsin creates opportunities for businesses to grow and utilize our strong workforce.”
“This latest expansion is to support our customers who are developing cutting-edge, often life-changing therapies,” said Graham Brearley, general manager of Catalent Biologics. “Through our expansion, we are thrilled to partner with the state to bring more high-tech jobs to the highly skilled people of Wisconsin and help make better treatments to positively impact patients around the world.”
The Wisconsin Economic Development Corporation (WEDC) is supporting the project by authorizing up to $1,300,000 in state income tax credits over the next three years. The actual amount of tax credits Catalent will receive is contingent upon the number of jobs created and the amount of capital investment during that period.
Mammalian cell culture capacity will be increased at the site with the buildout of two new biomanufacturing suites, providing additional clinical and commercial production at the 2,000- or 4,000-liter batch scale. Overall, the project will add approximately 60,000 square feet to the existing facility.
Expected to be completed by mid-2021, the expansion will more than double Catalent’s commercial biomanufacturing capacity at the site.
“I am pleased that Catalent has decided to continue expansion in Madison,” said Mayor Satya Rhodes-Conway. “Not only does the city benefit from new employment opportunities provided through this expansion project, but Catalent’s continued growth demonstrates that we are a community with a workforce, quality of life and business environment that can support growing international firms on the cutting edge of new technology.”
In addition to the 145 jobs expected to be created by Catalent, an economic modeling study by WEDC estimates the project could indirectly generate 206 additional jobs in the region. The 351 total new jobs are projected to generate $804,617 in annual state income taxes.
Catalent Inc. is a global provider of advanced delivery technologies, development and manufacturing solutions for drugs, biologics, gene therapies and consumer health products. Headquartered in Somerset, New Jersey, the company has more than 35 facilities across five continents, 13 of which are in the U.S.
According to the company’s 2018 annual report, Catalent produces approximately 72 billion doses for nearly 7,000 customer products, or approximately one in every 20 doses of such products taken by patients each year. They also hold about 1,200 patents and patent applications in advanced delivery, drug and biologics formulation, and manufacturing.